Stockreport

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral sessionPreclinical d [Read more]